Issue Date: August 4, 2017
Volume 44 • Issue 16 • Page 811
MARYLAND DEPARTMENT OF HEALTH
Subtitle 32 BOARD OF PHYSICIANS
10.32.02 Hearings Before the Board of Physicians
Authority: Health Occupations Article, §§14-205 and 14-405, Annotated Code of Maryland
Notice of Proposed Action
The Secretary of Health proposes to adopt new Regulation .17 under COMAR 10.32.02 Hearings Before the Board of Physicians. This action was considered at a public hearing held on April 26, 2017, notice of which was provided by posting on the Board’s website, http://www.mbp.state.us.forms/mar17FULLagenda.pdf, from April 12, 2017—April 26, 2017, General Provisions Article, §3-302(c), Annotated Code of Maryland.
Statement of Purpose
The purpose of this action is to add opioid prescribing guidelines of the Centers for Disease Control and Prevention as a consideration for the Board and disciplinary panel hearings.
Comparison to Federal Standards
There is no corresponding federal standard to this proposed action.
Estimate of Economic Impact
The proposed action has no economic impact.
Economic Impact on Small Businesses
The proposed action has minimal or no economic impact on small businesses.
Impact on Individuals with Disabilities
The proposed action has no impact on individuals with disabilities.
Opportunity for Public Comment
Comments may be sent to Michele Phinney, Director, Office of Regulation and Policy Coordination, Maryland Department of Health, 201 West Preston Street, Room 512, Baltimore, MD 21201, or call 410-767-6499 (TTY 800-735-2258), or email to email@example.com, or fax to 410-767-6483. Comments will be accepted through September 5, 2017. A public hearing has not been scheduled.
.17 Opioid Guidelines.
The Board and the disciplinary panels may consider the “Guideline for Prescribing Opioids for Chronic Pain” published by the Centers for Disease Control and Prevention, but this guideline is not binding on the Board or the disciplinary panels.
Secretary of Health